NCT00820950

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Ruxolitinib phosphate cream	Ruxolitinib phosphate cream 0.5%
DRUG	Dovonex® calcipotriene 0.005%	Cream applied once or twice daily for up to 56 days.
DRUG	Diprolene® AF betamethasone dipropionate 0.05% cream.	Cream applied once or twice daily for up to 56 days
DRUG	Placebo cream	Cream applied once or twice daily for 56 days
DRUG	Ruxolitinib phosphate cream	Ruxolitinib phosphate cream 1.0%
DRUG	Ruxolitinib phosphate cream	Ruxolitinib phosphate cream 1.5%

Timeline

• Start date: 2007-05-31
• Primary completion: 2009-01-31
• Completion: 2009-04-30
• First posted: 2009-01-12
• Last updated: 2022-02-08
• Results posted: 2022-02-08

Locations

6 sites across 1 country: United States